Since the report of Schoenbach and associates1on the use of stilbamidine in the treatment of blastomycosis, the diamidine group of drugs has been investigated for their therapeutic effects against various fungus infections.2Stilbamidine is a relatively unstable and toxic drug and is not acceptable as an experimental drug for the dermatomycoses. Recently*there was elaborated a more stable, related compound, 2-hydroxystilbamidine, which is less toxic than, and equally as effective as, its predecessor stilbamidine. Favorable results have been reported with its use not only in blastomycosis but also in histoplasmosis, coccidioidomycosis and leishmaniasis.†The incidence of kidney, liver, and hemopoietic effects seen after stilbamidine have been absent with 2-hydroxystilbamidine.‡There has been one doubtful report of fifth nerve neuropathy with 2-hydroxystilbamidine in 125 cases treated with the drug. In this patient there was a question of whether stilbamidin